BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge (NASDAQ: BIOA) reported positive topline Phase 1 data for oral NLRP3 inhibitor BGE-102, showing median hsCRP reductions of 86% across 60 mg and 120 mg once-daily cohorts and 87–93% of participants reaching hsCRP <2 mg/L. BGE-102 was well tolerated. The company plans two mid-2026 proof-of-concept trials (cardiovascular risk Phase 2 and DME Phase 1b/2a) with data expected by end-2026 and mid-2027. BioAge completed an upsized follow-on offering raising $132.3M. Q1 2026: collaboration revenue $2.8M, R&D $20.4M, G&A $7.7M, net loss $22.3M ($0.52), cash $384.9M; runway through 2029.
BioArctic (NYSE:B) reports that the FDA extended the PDUFA date for the sBLA for Leqembi Iqlik to August 24, 2026 after requesting additional information, which the agency classified as a major amendment and added a three‑month review period. The FDA has not raised approvability concerns to date.
Leqembi maintenance subcutaneous dosing received FDA action on August 26, 2025, and Leqembi is approved by more than 50 regulatory authorities worldwide. BioArctic and Eisai continue plans for joint Nordic commercialization.
BioAge (Nasdaq: BIOA) will host an R&D Day webcast on May 8, 2026 from 12:30–2:00 PM ET focused on BGE-102, an orally available NLRP3 inflammasome inhibitor. Management will present Phase 1 clinical data and the therapeutic rationale for ASCVD and retinal disease.
Four academic and clinical experts will join presentations and a live Q&A. A recording will be available in the company's Events section at the investor relations website.
BioArctic (Nasdaq: B) published its Annual Report 2025, with the Sustainability Report and Corporate Governance Report integrated into the document. The company highlights a breakthrough Alzheimer’s drug now on the global market, several licence agreements, a broad pipeline and record-high profits in 2025.
The report aligns sustainability reporting with the European CSRD and ESRS frameworks and is available for download from the company's investor website.
BioAge (Nasdaq: BIOA) reported Phase 1 data for oral NLRP3 inhibitor BGE-102, showing rapid, large reductions in inflammatory biomarkers. In participants with obesity and elevated hsCRP, 60 mg QD (21 days) and 120 mg QD (14 days) produced median hsCRP reductions of ~85% and ~83–86%, respectively.
BGE-102 was well tolerated with no serious adverse events. BioAge plans a Phase 2 cardiovascular risk trial in H1 2026 with data expected H2 2026, and a Phase 1b/2a DME trial beginning mid-2026 with results anticipated mid-2027.
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
BioArctic (Nasdaq: B) announces the Nomination Committee's proposals for the Annual General Meeting on May 28, 2026. The committee proposes an eight-member board, re-electing Eugen Steiner as chair and six existing members, and adding Philip Scheltens and Linda Nilsson as new board members.
Pär Gellerfors has declined re-election; Linda Nilsson is proposed to represent the Gellerfors family's holding company. The Nomination Committee members represent ~57% of shares and ~83% of votes.
BioAge (NASDAQ: BIOA) reported full-year 2025 results and Q4 updates on March 24, 2026. Key clinical highlights include positive interim Phase 1 data for oral NLRP3 inhibitor BGE-102 with an 86% median hsCRP reduction at 120 mg and planned Phase 2a initiation in 1H 2026. The company completed an upsized follow-on offering raising $132.3 million and held $285.1 million in cash and marketable securities as of December 31, 2025, estimating funding through 2029.
BioArctic (NASDAQ: B) reported new data presented at AD/PD 2026 on long-term, real-world IV lecanemab treatment persistence and additional company presentations. Real-world claims analysis showed 78.4% persistence at 18 months, 71.7% at 20 months and 67.3% at 24 months. BioArctic also presented data on lecanemab binding to soluble Aβ protofibrils and a poster on exidavnemab trial screening using alpha-synuclein SAA. The release notes investigational status and no guarantee of regulatory approval.
BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.
Contact details for investor relations are provided for further inquiries.